What's Going On With Bristol-Myers Squibb Shares Monday?
What's Going On With Bristol-Myers Squibb Shares Monday?
"While we are disappointed with the results, we are continuing to analyze the data to determine next steps," said Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie Inc (NYSE:ABBV) announced that its Phase 2 EMPOWER trials did not meet their primary endpoints.
施貴寶公司（NYSE：BMY）的股價週一有所上漲。股票似乎在艾伯維公司（NYSE：ABBV）宣佈其2期EMPOWER試驗未能達到主要終點後出現積極反應。
The Details: Abbvie announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia did not meet their primary endpoint.
詳情：艾伯維公司宣佈其兩項第2期EMPOWER試驗，研究emraclidine作爲一種每日一次的口服單藥治療方案，用於成年精神分裂症患者，並未達到其主要終點。
The trials failed to show a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6. While the clinical trials did not meet their primary endpoint, emraclidine was well-tolerated with a safety profile comparable to that observed in the Phase 1b trial.
試驗未能顯示在第6周與安慰劑組相比基線變化的陽性和陰性綜合症量表（PANSS）總分上的統計學顯著改善。雖然臨床試驗未能達到主要終點，emraclidine的耐受性良好，其安全性與第一期試驗中觀察到的相當。
"While we are disappointed with the results, we are continuing to analyze the data to determine next steps," said Roopal Thakkar, executive vice president, research and development, chief scientific officer, AbbVie.
「雖然我們對結果感到失望，但我們正在繼續分析數據以確定下一步行動，」艾伯維公司研發部執行副總裁、首席科學官Roopal Thakkar說。
"We would like to extend our gratitude to the study participants and their loved ones as well as to our network of clinical investigative sites for their participation in these trials. We are confident that our innovative pipeline will continue to bring meaningful therapies to patients, and we remain committed to finding better treatments for people living with psychiatric and neurological disorders."
「我們要感謝研究參與者及其親人，以及我們的臨床調查機構網絡，感謝他們參與這些試驗。我們相信我們創新的研發管線將繼續爲患者帶來有意義的療法，我們致力於爲患有精神疾病和神經疾病的人們尋找更好的治療。」
Related Link: AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
相關鏈接：艾伯維公司的精神分裂症藥物emraclidine「令人意外地令人失望」，分析師表示，管線被低估
AbbVie is a large pharmaceutical company with a strong focus on immunology and neuroscience, while Bristol-Myers Squibb, though smaller, emphasizes therapies in oncology and cardiovascular disease.
艾伯維公司是一家專注於免疫學和神經科學的大型藥品公司，而施貴寶公司雖然規模較小，但側重於癌症和心血管疾病的治療。
The U.S. Food and Drug Administration approved Karuna Therapeutics' KarXT in September. It was the first schizophrenia drug to be approved since the 1950s. Bristol-Myers Squibb acquired Karuna Therapeutics for $330 per share in cash last year.
美國食品藥品監督管理局已於去年9月批准karuna therapeutics的KarXt。這是自上世紀50年代以來首個獲批的精神分裂症藥物。施貴寶公司去年以每股330美元的現金收購了karuna therapeutics。
BMY Price Action: At the time of publication, Bristol-Myers Squibb stock is up 11% at $60.12, according to data from Benzinga Pro.
BMY股價走勢：根據Benzinga Pro的數據，在發佈時，施貴寶股價上漲11%，報60.12美元。
Image: Courtesy of Bristol Myers Squibb
圖片：由施貴寶公司提供
譯文內容由第三人軟體翻譯。
